
Gene Therapy for Hemophilia
This video gives a quick introduction to gene therapy for hemophilia. Learn more about different treatment options for hemophilia with
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

This video gives a quick introduction to gene therapy for hemophilia. Learn more about different treatment options for hemophilia with

This video gives a quick introduction to hemostatic rebalancing therapy. Learn more about different treatment options for hemophilia with the

This fact sheet contains commonly asked questions and more information on gene therapy for hemophilia A. Learn more about different

This fact sheet contains commonly asked questions and more information on hemostatic rebalancing therapy. Learn more about different treatment options

This fact sheet contains commonly asked questions and more information on bispecific antibody therapy. Learn more about different treatment options

This video gives a quick introduction to extended half-life (EHL) clotting factor replacement therapy. Learn more about different treatment options